AstraZeneca-Merck's Lynparza gets U.S. FDA nod for prostate cancer treatment

The U.S. Food and Drug Administration approved AstraZeneca Plc and Merck&Co Inc's Lynparza as a treatment for a form of prostate cancer, the companies said in a joint statement on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Publication date: Available online 22 May 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Giandomenico Roviello, Benedetta Panella
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 22 May 2020Source: European UrologyAuthor(s): Steven M. Monda, Marc Arnaldo Dall’Era
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 22 May 2020Source: European UrologyAuthor(s): Cameron Herberts, Andrew J. Murtha, Simon Fu, Gang Wang, Elena Schönlau, Hui Xue, Dong Lin, Anna Gleave, Steven Yip, Arkhjamil Angeles, Sebastien Hotte, Ben Tran, Scott North, Sinja Taavitsainen, Kevin Beja, Gillian Vandekerkhove, Elie Ritch, Evan Warner, Fred Saad, Nayyer Iqbal
Source: European Urology - Category: Urology & Nephrology Source Type: research
Authors: Holly JMP, Biernacka K, Perks CM Abstract Introduction: Preclinical, clinical, and population studies have provided robust evidence for an important role for the insulin-like growth factor (IGF) system in the development of prostate cancer.Areas covered: An overview of the IGF system is provided. The evidence implicating the IGF system in the development of prostate cancer is summarized. The compelling evidence culminated in a number of clinical trials of agents targeting the system; the reasons for the failure of these trials are discussed.Expert opinion: Clinical trials of agents targeting the IGF system...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Conditions:   Prostate Cancer;   Radical Prostatectomy Intervention:   Combination Product: Microdevice Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: - Category: Research Source Type: clinical trials
In this study, we found that the enhancer of zeste homolog 2 (EZH2), which catalyzes the methylation at lysine 27 of histone H3, is a target of USP7 and is stabilized by USP7-mediated deubiquitination. In prostate cancer cells, the transcriptional repression function of EZH2 was inhibited by USP7-knockdown. Furthermore, ectopic introduction of EZH2 restored the cell migration, invasion, and sphere-forming potential of prostate cancer cells, which had been decreased by USP7-knockdown. Moreover, combined treatment with the USP7-specific inhibitor P5091 and EZH2 inhibitors, such as GSK126, EPZ6438, and DZNep, induced synergis...
Source: Genetics and Molecular Biology - Category: Genetics & Stem Cells Source Type: research
Cell Death &Disease, Published online: 23 May 2020; doi:10.1038/s41419-020-2569-yLncRNA SNHG17 aggravated prostate cancer progression through regulating its homolog SNORA71B via a positive feedback loop
Source: Cell death and disease - Category: Internal Medicine Authors: Source Type: research
Nature Reviews Clinical Oncology, Published online: 23 May 2020; doi:10.1038/s41571-020-0395-xMature results of the PROfound study demonstrate that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib prolongs progression-free survival compared with second-generation hormonal therapies in men with metastatic castration-resistant prostate cancer harbouring BRCA1, BRCA2 or ATM mutations. However, a closer look at the efficacy of olaparib on a gene-by-gene basis suggests that its activity is most pronounced in BRCA2-mutant prostate cancers and might not be equally active in all homologous recombination repair-deficient cancers.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: GS 4 + 4 in patients with PC was associated with better OS and positive surgical margin rates. It seems likely that there is heterogeneity within ISUP GG 4. However, caution should be exercised in interpreting the conclusions drawn from this study, given the limitations of the study, which include the heterogeneity of the population of interest and the retrospective nature of the primary data evaluated. PMID: 32432435 [PubMed - as supplied by publisher]
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
More News: AstraZeneca | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Merck | Prostate Cancer